tiprankstipranks
Advertisement
Advertisement
Ipsen Advances Elafibranor Into Phase III For Rare Liver Disease, Signaling Long-Term Upside Potential
PremiumCompany AnnouncementsIpsen Advances Elafibranor Into Phase III For Rare Liver Disease, Signaling Long-Term Upside Potential
4M ago
Ipsen Completes Key Liver-Function Study for Palovarotene, Trimming Risk for Investors
Premium
Company Announcements
Ipsen Completes Key Liver-Function Study for Palovarotene, Trimming Risk for Investors
4M ago
Ipsen Advances Phase III Aesthetics Bet With New IPN10200 Frown-Line Study
Premium
Company Announcements
Ipsen Advances Phase III Aesthetics Bet With New IPN10200 Frown-Line Study
4M ago
Ipsen’s Genetic Study on PFIC: A Potential Game-Changer for Liver Disorder Diagnosis
PremiumCompany AnnouncementsIpsen’s Genetic Study on PFIC: A Potential Game-Changer for Liver Disorder Diagnosis
8M ago
Ipsen’s New Study on IPN60300: A Potential Game-Changer for Advanced Tumours
Premium
Company Announcements
Ipsen’s New Study on IPN60300: A Potential Game-Changer for Advanced Tumours
8M ago
Ipsen’s New Study on IPN01203: A Potential Game-Changer for Advanced Tumour Treatment
Premium
Company Announcements
Ipsen’s New Study on IPN01203: A Potential Game-Changer for Advanced Tumour Treatment
8M ago
Ipsen’s New Study on Palovarotene: Implications for Liver-Impaired Patients
PremiumCompany AnnouncementsIpsen’s New Study on Palovarotene: Implications for Liver-Impaired Patients
10M ago
Ipsen’s Odevixibat Study: A Closer Look at Pregnancy and Lactation Safety
Premium
Company Announcements
Ipsen’s Odevixibat Study: A Closer Look at Pregnancy and Lactation Safety
10M ago
Ipsen’s Latest Clinical Study on IPN01194: A Potential Game-Changer in Oncology
Premium
Company Announcements
Ipsen’s Latest Clinical Study on IPN01194: A Potential Game-Changer in Oncology
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100